


**Product Name: Recombinant Mouse TGFBR1 (C-Fc)**  
**Catalog #: PHM2164**



## Summary

<b>Name</b>	TGFBR1/ALK-5/TGF-beta receptor type-1
<b>Purity</b>	Greater than 95% as determined by reducing SDS-PAGE
<b>Endotoxin level</b>	<1 EU/μg as determined by LAL test.
<b>Construction</b>	Recombinant Mouse TGF-beta Receptor Type-1 is produced by our Mammalian expression system and the target gene encoding Leu30-Glu125 is expressed with a human IgG1 Fc tag at the C-terminus.
<b>Accession #</b>	Q64729
<b>Host</b>	Human Cells
<b>Species</b>	Mouse
<b>Predicted Molecular Mass</b>	37.6 KDa
<b>Formulation</b>	Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
<b>Stability&amp;Storage</b>	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
<b>Reconstitution</b>	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

## SDS-PAGE image



## Background

**Product Name: Recombinant Mouse TGFBR1 (C-Fc)**  
**Catalog #: PHM2164**

---



**Alternative Names**

AAT5; activin A receptor type II-like kinase, 53kD; ACVRLK4; ALK-5; ALK-5ALK5; LDS1A; LDS2A; SKR4; tbetaR-I; TGFB1R1; TGF-beta receptor type I; TGFbetaRI; TGFBR1; TGF-bRI; TGFR-1

**Background**

TGF-beta RI, also called ALK-5, is an approximately 55 kDa type I transmembrane serine/threonine receptor kinase. In the presence of TGF-beta, TGF-beta RI forms a complex with, and is phosphorylated by, TGF-beta RII. Phosphorylated TGF-beta RI can then transiently bind and phosphorylate Smad2 and Smad3. TGF-beta functions as a tumor suppressor by inhibiting the cell cycle in the G1 phase. Administration of TGF-beta is able to protect against mammary tumor development in transgenic mouse models in vivo. Disruption of the TGF-beta/SMAD pathway has been implicated in a variety of human cancers, with the majority of colon and gastric cancers being caused by an inactivating mutation of TGF-beta RII. TGF-beta RI is likely important during development, since mice deficient for TGF-beta RI die at midgestation with severe defects in vascular development of the yolk sac and placenta, and an absence of circulating red blood cells. Furthermore, TGF-beta RI appears to be involved in proper lymphatic network development.

**Note**

For Research Use Only , Not for Diagnostic Use.